Blueprint Medicines Welcomes David Schenkein, M.D., to its Board of Directors
Blueprint Medicines Welcomes David Schenkein, M.D., to its Board of Directors
February 25, 2013 at 5:08 PM EST
Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.